Objectives Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA). despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describes the response to MTX monotherapy in newly diagnosed patients with PsA in usual care. https://www.bekindtopets.com/